Loading…
Boston Scientific completed its acquisition of Symetis SA, a Swiss TAVI device company, for $435 million in cash, expanding its structural heart portfolio.
Boston Scientific Corporation announced the close of its acquisition of Symetis SA, a Swiss structural heart company, for $435 million in cash. The deal was originally announced on March 30, 2017.
Boston Scientific Corporation announced a definitive agreement to acquire Symetis SA, a Swiss structural heart company, for $435 million in up-front cash. The acquisition expands Boston Scientific's TAVI portfolio and is expected to close in Q2 2017.